Effectiveness of Switching HIV Treatment to DOR/3TC/TDF
Author Information
Author(s): Cicalini Stefania, Lanini Simone, Gagliardini Roberta, Bellagamba Rita, Vergori Alessandra, Mastrorosa Ilaria, Mazzotta Valentina, Esvan Rozenn, Plazzi Maria Maddalena, Ottou Sandrine, Grilli Elisabetta, De Zottis Federico, Fusto Marisa, Paulicelli Jessica, Antinori Andrea, Berzal-Herranz Alfredo, Resino Salvador, Sepúlveda-Crespo Daniel
Primary Institution: National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS
Hypothesis
Is switching to a regimen of doravirine (DOR), tenofovir disoproxil fumarate (TDF), and lamivudine (3TC) effective for people living with HIV who are experienced with other treatments?
Conclusion
Switching to DOR/3TC/TDF from RPV/TDF/FTC is effective and well-tolerated for people living with HIV.
Supporting Evidence
- The treatment failure rate was only 2.34%.
- CD4 counts improved significantly by about 50 cells/µL.
- The regimen did not cause adverse metabolic effects.
- Most participants maintained viral suppression.
- Switching to DOR/3TC/TDF was well-tolerated.
- Participants had been virologically suppressed for a median of 6 years.
- Significant improvements were observed in immunological parameters.
- The study supports ongoing research for ART regimens.
Takeaway
This study shows that changing HIV treatment to a new combination of drugs can help people stay healthy without causing bad side effects.
Methodology
This was a retrospective cohort study analyzing 426 people living with HIV who switched from RPV/FTC/TDF to DOR/3TC/TDF.
Potential Biases
Potential biases associated with retrospective data collection and lack of a control group.
Limitations
The study's retrospective design and single-center setting may limit the generalizability of the findings.
Participant Demographics
Median age was 47 years, with 69.48% males and 14.79% non-Caucasian individuals.
Statistical Information
P-Value
p < 0.001
Confidence Interval
95% CI, 1.28–4.50%
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website